Luke Mountjoy
0000-0001-5140-8346
Publication & Citation Trends
Publications
0 total
Biomarker Correlates of Clinical Outcomes from a Global phase 1b Study of JNJ-90014496, CD20/CD19 Bi-Specific Chimeric Antigen Receptor (CAR) T-cell Therapy for Patients with Large B-cell Lymphoma (LBCL)
Cited by 0
Semantic Scholar
ZUMA-25 preliminary analysis: A Phase 2 study of brexucabtagene autoleucel (brexu-cel) in patients (Pts) with relapsed/refractory (R/R) burkitt lymphoma (BL), substudy C
Cited by 0
Semantic Scholar
Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement
Cited by 1
Semantic Scholar
CT-1498: A Global Phase 1B Study of JNJ-90014496, A CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Cited by 0
Semantic Scholar
Firicabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial)
Cited by 0
Semantic Scholar
NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival
Cited by 0
Semantic Scholar
POSTER: CT-1498 A Global Phase 1B Study of JNJ-90014496, A CD19/CD20 Bi-Specific Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Cited by 0
Semantic Scholar
A GLOBAL PHASE 1B STUDY OF JNJ‐90014496, A CD19/CD20 BI‐SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) T‐CELL THERAPY, IN RELAPSED/REFRACTORY (R/R) LARGE B‐CELL LYMPHOMA (LBCL)
Cited by 0
Semantic Scholar
Research Topics
CAR-T cell therapy research
(41)
Acute Lymphoblastic Leukemia research
(26)
Hematopoietic Stem Cell Transplantation
(8)
Lymphoma Diagnosis and Treatment
(7)
Chronic Lymphocytic Leukemia Research
(6)
Affiliations
University College London Hospitals NHS Foundation Trust
University Hospitals Bristol NHS Foundation Trust
Newcastle upon Tyne Hospitals NHS Foundation Trust
University Hospital Augsburg
WinnMed